Abstracts tagged "Cardiovascular"

Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Aleydis Gonzalez Melendez¹, Rebeca L. Polina-Lugo¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Osvaldo Uresti³, Ricardo I. de la Rosa-Vazquez³, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0994 • ACR Convergence 2024
Association Between Cardiovascular Risk Factors and the Onset of Giant Cell Arteritis: A Systematic Review and Meta-analysis
François Barde¹, Lucas Pacoureau², Alexis Elbaz², Raphaele Seror³ and Yann Nguyen⁴, ¹Inserm, CESP, Paris, France, ²Inserm, CESP, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁴Université Paris Saclay, Clichy, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) predominantly affects people over 50 years of age, with a female predominance. Its pathophysiological mechanism is currently under debate. In…
Abstract Number: 1393 • ACR Convergence 2024
Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Roy Fleischmann¹, Zoltán Szekanecz², Eduardo Mysler³, Kevin Winthrop⁴, Kunihiro Yamaoka⁵, Kirsten Famulla⁶, Yanna Song⁷, Birgit Kovacs⁷, Sander Strengholt⁸ and Gerd Burmester⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Debrecen, Debrecen, Hungary, ³Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵Kitasato University School of Medicine, Sagamihara, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁷AbbVie, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 2245 • ACR Convergence 2024
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalén Calvo⁴, Concepción Aranda-Valera⁵, María Lourdes Ladehesa-Pineda¹, Pilar Font², Ismael Sánchez Pareja², Elena Moreno-Caño⁵, María Carmen Ábalos-Aguilera⁶, Christian Merlo-Ruiz⁶, Mª Angeles Aguirre-Zamorano⁷, Tomás Cerdó², Nuria Barbarroja², Carlos Perez-Sanchez² and Alejandro Escudero-Contreras², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain
Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
Abstract Number: 0313 • ACR Convergence 2024
Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Sehreen Mumtaz¹, Jayesh Valecha², Andy Abril³, Florentina Berianu³, Benjamin Wang⁴, Ronald Butendieck⁴, anushka Irani², carolyn mead harvey² and Vikas Majithia², ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Jacksonville, FL
Background/Purpose: Sarcoidosis, characterized by non-necrotizing granulomatous inflammation, is a multisystem disease with an unpredictable disease spectrum. An estimated 5% of sarcoidosis patients have clinically evident…
Abstract Number: 0647 • ACR Convergence 2024
Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Pankti Mehta¹, Fadi Kharouf², Qixuan Li³, Laura Patricia Whittall Garcia³, Dafna Gladman⁴ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Pericarditis is an important feature in the classification criteria and disease activity assessments in Systemic Lupus Erythematosus (SLE). We aimed to study the prevalence,…
Abstract Number: 1011 • ACR Convergence 2024
Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Jeffrey Curtis¹, Danielle M Conrad², Whitney S Krueger², Andrew P Gara² and Kevin Winthrop³, ¹FASTER Medicine, Hoover, AL, ²AbbVie, North Chicago, IL, ³School of Medicine, Oregon Health and Science University, Portland, OR
Background/Purpose: The risk of herpes zoster (HZ) is increased in patients with inflammatory arthritis (IA); although the Shingrix vaccine has been available since 2017, its…
Abstract Number: 1440 • ACR Convergence 2024
Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors
Brona Dinneen¹ and Finbar O'Shea², ¹St James's Hospital,, Dublin, Dublin, Ireland, ²St James's Hospital, Dublin, Dublin, Ireland
Background/Purpose: The EULAR cardiovascular screening recommendations advocate for the use of carotid dopplers in patients with inflammatory joint diseases to detect subclinical atherosclerosis. Despite these…
Abstract Number: 1791 • ACR Convergence 2024
A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Matthew Muller¹, Elliot Luttrell-Williams¹, Haley Rosmann², Kelly Ruggles³, Jill Buyon⁴ and Jeffrey Berger¹, ¹NYU Langone, New York City, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, Brooklyn, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…
Abstract Number: 2259 • ACR Convergence 2024
Effects of Anti-Obesity Medications in RA Patients
Elizabeth Dente¹, David Kellner², Vincent Tran², Travis Welsh², Victor Tran³, Angshuman Saha¹, Jenny Brook¹, David Elashoff⁴ and Veena Ranganath², ¹UCLA, Los Angeles, ²UCLA, Los Angeles, CA, ³UCLA, Costa Mesa, CA, ⁴UCLA Department of Medicine Statistics Core, Los Angeles
Background/Purpose: It is standard practice to advocate for weight loss in patients with rheumatoid arthritis (RA) and obesity. Obesity and rheumatoid arthritis are both independently…
Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Gianluca sambataro², iazsmin Ventura³, Francisca Bozan⁴, Eduardo Dourado⁵, Sara Faghihi-Kashani⁶, Aravinthan Loganathan⁷, Daphne Rivero Gallegos⁸, Akira Yoshida⁹, Giovanni Zanframundo¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Andrew Mammen¹⁸, Neil McHugh¹⁹, Frederick Miller²⁰, Carlomaurizio Montecucco²¹, Antonella Notarnicola²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo A. Scire²⁶, Albert Gil-Vila²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²University of Catania, Catania, Italy, ³Section of Rheumatology, University of Chicago, Chicago, IL, ⁴Hospital Clinico Universidad de Chile, Santiago, Chile, ⁵Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸INER, Ciudad de México, Mexico State, Mexico, ⁹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹⁰Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸NIH, Bethesda, MD, ¹⁹University of Bath, Bath, United Kingdom, ²⁰NIH, NIEHS, Chapel Hill, NC, ²¹IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²²Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Universitat Autònoma of Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
Abstract Number: 0675 • ACR Convergence 2024
Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series
Swetapadma Tripathy¹, Davina Chen², Lanny DiFranza³ and Bibi Ayesha⁴, ¹Montefiore Medical Center, Forest Hills, NY, ²Montefiore Medical Center, New Rochelle, NY, ³Montefiore Medical Center, New York City, NY, ⁴Montefiore Medical Center, Metuchen, NJ
Background/Purpose: Cardiomyopathy is a rare, life-threatening adverse effect of hydroxychloroquine (HCQ) use. There is a paucity in literature regarding treatment and prognosis in these cases. The aim…
Abstract Number: 1033 • ACR Convergence 2024
Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Muhammad Naveed¹, Farman Ali², Ahila Ali¹, Bazil Azeem³, Faizan Ahmed⁴, Rabia Iqbal¹, Muhammad Omer Rehan¹, Nouman Shafique⁵, Syed Ishaq⁶, Aman Ullah⁷ and Sherif Eltawansy⁸, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Corewell Health, Dearborn Hospital, Dearborn, MI, Dearborn, MI, ³Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁴Ameer-ud-Din Medical College, Lahore, Pakistan, ⁵AdventHealth Orlando, Orlando, FL, ⁶Sinai Hospital of Baltimore, Baltimore, MD, ⁷SSM Health St Louis University Hospital, St. Louis, MO, ⁸Jersey Shore University Medical Centre, Neptune, NJ
Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…

1
2
3
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.